Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, because inefficacy or intolerable side effects, some patients do not benefit. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals